How to prove the concerned price if the specialty is not yet produced? What is the value of a proven pricing structure if the price is downsized over time? Lets discuss to overcome this bottleneck.
You dive into a simulation model and at first everything seems flawless. But with each adjustment the risk of flaws creeping into the programming.
The 'ICER' is a well-known measure to assess the extra cost to invest to win one QALY. In Belgium, unofficially 35 000 € / QALY gained is often applied as benchmark, the 'willingness to pay' (WTP). But does the payer invest the budget in function of the potential medical need or not ?
A model contains a large amount of inputs and every single input will be surrounded with uncertainty and the end result will be a translation of the composite effect of all inputs and their potential variance.
How to indicate if an innovation is worthwhile to pay for in view of the claimed benefit it will bring? The goal of the NMB is to compare two interventions by subtracting the NMB of ‘intervention A’ from the NMB of ‘intervention B’, resulting in the incremental NMB (iNMB).
Do you understand the potential impact of using 2 independent datasets? In this blog, we provide you a taste of some basic insights.
Always wondered how health economic models work? Good news: this blog is developed to guide you through the basic elements of ‘health state transition models’.
All market access colleagues involved in the preparation of economic files will be confronted with the aspect of inflation. There are 2 viewpoints versus ‘today’.
If you estimate a market share and present this to the sales and marketing department, their input will show high variance. How can you reduce that variance and how can you achieve the best and realistic estimation of the market shares?
HTA bodies should take indirect costs in the scope to assess the cost/benefit of innovation.
